^
    4d
    Multi-sampling allows intra-tumoral heterogeneity querying and vulnerability profiling in glioblastoma. (PubMed, Neuro Oncol)
    This work demonstrates the regional heterogeneity of therapeutic vulnerabilities in GBM ex vivo, showing various drugs with tumor-wide or MRI-enhancement informed activity. These findings offer preclinical bases of numerous monotherapies and drug combinations for future clinical trial design.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    navitoclax (ABT 263) • ulixertinib (BVD-523) • CC-115 • paxalisib (GDC-0084) • trotabresib (BMS-986378)
    over1year
    A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas (clinicaltrials.gov)
    P1, N=139, Terminated, Celgene | Active, not recruiting --> Terminated; Business objectives have changed
    Trial termination • First-in-human
    |
    trotabresib (BMS-986378)
    over1year
    Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer (clinicaltrials.gov)
    P1, N=41, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed
    Trial completion
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • BRD4 (Bromodomain Containing 4) • BRD3 (Bromodomain Containing 3)
    |
    MYCN amplification
    |
    ezobresib (BMS-986158) • trotabresib (BMS-986378)
    over1year
    A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas (clinicaltrials.gov)
    P1, N=139, Active, not recruiting, Celgene | Trial completion date: Jun 2026 --> Sep 2024
    Trial completion date • First-in-human
    |
    trotabresib (BMS-986378)
    almost2years
    Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer (clinicaltrials.gov)
    P1, N=41, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Jul 2024 --> Mar 2024
    Trial primary completion date
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • BRD4 (Bromodomain Containing 4) • BRD3 (Bromodomain Containing 3)
    |
    ezobresib (BMS-986158) • trotabresib (BMS-986378)
    almost2years
    A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P1, N=184, Terminated, Celgene | Trial completion date: May 2026 --> Jul 2024 | Active, not recruiting --> Terminated; Business objectives have changed
    Trial completion date • Trial termination • Combination therapy
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    temozolomide • trotabresib (BMS-986378)
    almost2years
    CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma (clinicaltrials.gov)
    P1, N=20, Terminated, Celgene | Completed --> Terminated; Business objectives have changed.
    Trial termination
    |
    trotabresib (BMS-986378)
    almost2years
    CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma (clinicaltrials.gov)
    P1, N=20, Completed, Celgene | Active, not recruiting --> Completed
    Trial completion
    |
    trotabresib (BMS-986378)
    2years
    A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=0, Withdrawn, Bristol-Myers Squibb | Not yet recruiting --> Withdrawn
    Trial withdrawal • Metastases
    |
    trotabresib (BMS-986378)
    2years
    Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis (clinicaltrials.gov)
    P1, N=0, Withdrawn, Northwestern University | N=34 --> 0 | Trial completion date: Dec 2031 --> Mar 2024 | Initiation date: Dec 2024 --> Dec 2023 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2029 --> Mar 2024
    Enrollment change • Trial completion date • Trial initiation date • Trial withdrawal • Trial primary completion date • Combination therapy
    |
    vinorelbine tartrate • trotabresib (BMS-986378)
    2years
    Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis (clinicaltrials.gov)
    P1, N=34, Not yet recruiting, Northwestern University | Initiation date: Dec 2023 --> Dec 2024
    Trial initiation date • Combination therapy
    |
    vinorelbine tartrate • trotabresib (BMS-986378)
    2years
    Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer (clinicaltrials.gov)
    P1, N=41, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | N=66 --> 41 | Trial completion date: Jun 2025 --> Jul 2024
    Enrollment closed • Enrollment change • Trial completion date
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • BRD4 (Bromodomain Containing 4) • BRD3 (Bromodomain Containing 3)
    |
    MYCN amplification
    |
    ezobresib (BMS-986158) • trotabresib (BMS-986378)